Jun 11, 2020
Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology
Jun 03, 2020
Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis
Jun 03, 2020
Rigel to Present Four Posters Highlighting IRAK1/4 Inhibitor at the EULAR 2020 E-Congress
May 12, 2020
Curis Reports First Quarter 2020 Financial Results
Dec 06, 2019
Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study
Nov 11, 2019
Kymera Therapeutics to Present Preclinical Data on its First-in-Class IRAK4 Degraders Demonstrating Robust Inhibition of Inflammatory Responses and Superiority to IRAK4 Kinase Inhibitors
Nov 06, 2019
Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology
Jun 12, 2019
Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS
Mar 01, 2019
Kymera Therapeutics to Present New Preclinical Data of IRAK4 Degraders in MYD88-Mutant Lymphoma at American Association for Cancer Research Annual Meeting
Dec 03, 2018
Kymera Therapeutics Presents First Validation of IRAK4 Protein Degraders in MYD88-Mutant Lymphoma
Jun 26, 2018
Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases
Jan 17, 2018
Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma